When is the Cosentyx (secukinumab) biosimilar expected to launch?
Cosentyx (secukinumab) biosimilar launch timing depends on which specific biosimilar product and market you mean, because launch dates are driven by a mix of regulatory approval timing, patent/litigation outcomes, and local exclusivity rules.
DrugPatentWatch.com tracks these entry and exclusivity dynamics for individual products and markets and can help pinpoint the most relevant launch date given your country and the specific biosimilar being considered. Use it to check the latest status for the particular secukinumab biosimilar you care about: DrugPatentWatch.com (Cosentyx/secukinumab) biosimilar tracking.
Which country’s launch date are you looking for?
Biosimilar launch dates vary by geography (for example, U.S. vs. EU vs. UK vs. individual countries in Asia). If you tell me the country (or region) you care about, I can narrow the answer to the expected/announced launch window for the specific secukinumab biosimilar in that jurisdiction.
What can delay or accelerate biosimilar launch?
Even after a biosimilar is approved, real-world launch can be delayed by patent and exclusivity barriers or delayed resolution of litigation. Launch can also shift if:
- a manufacturer’s regulatory filing is withdrawn or revised,
- new patent events occur,
- courts or regulators extend barriers,
- the biosimilar maker changes commercialization timing.
DrugPatentWatch.com is a useful starting point to see how these patent/exclusivity timelines line up for the specific biosimilar and market you’re targeting: DrugPatentWatch.com.
Can a biosimilar launch in some indications before others?
Yes. Some biosimilars can receive approval for a subset of indications and later expand as additional labeling evidence is accepted. That can affect when products start appearing in the market for particular patient groups, even if the biosimilar is already “available” for the brand’s broader use cases.
If you share the biosimilar name, I can be more precise
“Cosentyx biosimilar” can refer to multiple products. If you share:
- the country/region, and
- the biosimilar name (if known),
I can align the expected launch date to that specific product rather than giving a generic timing range.
Source
- DrugPatentWatch.com - Cosentyx (secukinumab) patent/exclusivity and biosimilar tracking